Leerink Partners Maintains Outperform on WAVE Life Sciences, Raises Price Target to $22

Benzinga · 10/16 17:15
Leerink Partners analyst Mani Foroohar maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises the price target from $20 to $22.